Comparing two forms of mexiletine for non-dystrophic myotonias
Part of Brain & nervous system clinical trials.
This trial compares a new extended-release (PR) form of mexiletine to the immediate-release (IR) form in people with non-dystrophic myotonias. The goal is to see if the longer-acting version works as well or better with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have myotonia congenita, paramyotonia congenita, or sodium channel myotonia confirmed by genetic testing.
- You are at least 16 years old.
- You are not pregnant or nursing, and you use effective birth control if needed.
- You have no significant heart problems, as checked by a cardiologist.
- You have handgrip myotonia (delayed relaxation of your grip lasting 3 seconds or more).
- You have not taken other anti-myotonic drugs (like flecainide or carbamazepine) within 4 weeks before the study starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a once-daily drug called mexiletine PR to see if it can help reduce muscle stiffness (myotonia) in people with myotonic dystrophy type 1 or 2. It may be a good option if you have a confirmed genetic diagnosis and are at least 16 years old.
This study tests if a daily capsule of mexiletine is safe and helpful over 26 weeks for people with myotonic dystrophy type 1 or 2. It's for people who finished a previous related study and want to continue treatment.
This study follows children under 6 years old with genetic myotonic disorders who are taking or may take mexiletine. It helps doctors understand how well the medicine works and if it is safe over time.
This trial tests whether mexiletine hydrochloride can help men with spinal and bulbar muscular atrophy (SBMA) by improving muscle strength and function. It may be an option if you have mild to moderate symptoms and meet heart and medication safety checks.
This trial tests an experimental oral medication called NMD670 for people with myasthenia gravis (MG). It aims to see if the drug is safe and if it helps improve muscle strength and daily function.
This trial is testing a new drug called SRP-1003 for people with myotonic dystrophy type 1 (DM1) who developed symptoms after age 12. The goal is to see if it can reduce muscle problems like myotonia (difficulty relaxing muscles) and improve daily function.
Hear when a new Myotonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.